You are here

generics

FDA generic approvals hit a new record, but the effort's not paying off yet

FDA generic approvals hit a new record, but the effort's not paying off yet

Fierce Pharma

Flag link:

Another Record Year for Generic Drug Approvals but Questions on Competition Remain

Another Record Year for Generic Drug Approvals but Questions on Competition Remain

RAPS.org

generic approvals

Flag link:

Have FDA’s Generic Approvals Helped With Competition? Researchers Say Too Early to Tell

Have FDA’s Generic Approvals Helped With Competition? Researchers Say Too Early to Tell

RAPS.org

Flag link:

The return of Vioxx: Can a drug once deemed deadly be relaunched to treat rare disease?

The return of Vioxx: Can a drug once deemed deadly be relaunched to treat rare disease?

Stat

Tremeau Pharmaceuticals

hemophilic arthropathy

Flag link:

Gilead scores PrEP approval for Descovy — kicking off marketing push before Truvada generics swarm

Gilead scores PrEP approval for Descovy — kicking off marketing push before Truvada generics swarm

Endpoints

Gilead Sciences

Flag link:

GlaxoSmithKline halts generic Zantac supply as global threat gains steam

GlaxoSmithKline halts generic Zantac supply as global threat gains steam

Fierce Pharma

product recalls

Flag link:

Pharma companies admit to sharing 'sensitive' info to keep prices high

Pharma companies admit to sharing 'sensitive' info to keep prices high

Fierce Pharma

King Pharmaceuticals

Alissa Healthcare

Flag link:

US judge paves way for branded and generic opioid makers to face landmark October trial

US judge paves way for branded and generic opioid makers to face landmark October trial

Endpoints

Flag link:

Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilar

Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilar

Pharmaforum

Flag link:

Mylan's Lantus copy derailed in U.S. again by manufacturing ills

Mylan's Lantus copy derailed in U.S. again by manufacturing ills

Fierce Pharma

drug manufacturing

Flag link:

Mylan's Newly-Approved Alimta Generic Will Not be Sold Until 2022

Mylan's Newly-Approved Alimta Generic Will Not be Sold Until 2022

BioSpace

Flag link:

Mylan up on OK for generic of Lilly’s $2bn cancer drug Alimta

Mylan up on OK for generic of Lilly’s $2bn cancer drug Alimta

Pharmaforum

non-squamous non-small cell lung cancer

Flag link:

Analysis Shows Eli Lilly’s Half-Price Humalog Generic Is Not Readily Available Across the U.S.

Analysis Shows Eli Lilly’s Half-Price Humalog Generic Is Not Readily Available Across the U.S.

BioSpace

Flag link:

Novo Nordisk and Mylan Battle Over Generic Versions of Victoza

Novo Nordisk and Mylan Battle Over Generic Versions of Victoza

BioSpace

Flag link:

Lyrica looking grim: Pfizer blockbuster's market share crumbles under generic attack

Lyrica looking grim: Pfizer blockbuster's market share crumbles under generic attack

Fierce Pharma

Flag link:

Generic Drug Approvals Hit Another Record High as Competition, Quality Questions Linger

Generic Drug Approvals Hit Another Record High as Competition, Quality Questions Linger

RAPS.org

Flag link:

Sanofi defends top oncology drug with Jevtana patent win

Sanofi defends top oncology drug with Jevtana patent win

Fierce Pharma

Flag link:

3 generic drugmakers accused of 'stonewalling' congressional probe

3 generic drugmakers accused of 'stonewalling' congressional probe

Beckers Hospital Review

Teva Pharmaceutical

Heritage Pharmaceuticals

Flag link:

Dr. Reddy's Copaxone, NuvaRing generics derailed by FDA

Dr. Reddy's Copaxone, NuvaRing generics derailed by FDA

Fierce Pharma

Teva Pharmaceutical

Flag link:

What Enbrel needs to do after its patent win

What Enbrel needs to do after its patent win

EP Vantage

Flag link:

Pages